Abstract

Mental and neurological disorders account for 10% of Disability Adjusted Life Years lost (DALY). people suffering from recurrent and progressive medical conditions have a higher risk of developing mental health problems. Psoriasis is one such disease where psychiatric comorbidities are more prominent and common and have a negative impact on mental health leading to a poorer prognosis. Aim and objectives: This study was conducted to determine the incidence of anxiety and depression in psoriasis patients, as well as to correlate these with psoriasis severity and quality of life. Materials and Methods: This study was done at a tertiary care hospital at Mamata General Hospital Khammam and Mamata Academy of Medical Sciences, Hyderabad over a period of 3 months on psoriasis patients. Psoriasis Area and Severity Index were used to assess the severity of psoriasis. PHQ-9, Perceived stress scale, and GAD -7 were used for screening depression, perceived stress, and anxiety respectively. WHOQOL-BREF was used to assess the quality of life. Statistical Analysis: Statistical Analysis was performed using Microsoft excel software and SPSS . Results: A sum of 69 subjects had anxiety and 71 subjects had depression. 51 patients had significant stress. A remarkable positive correlation was established between psoriasis variables like severity and duration of psoriasis and psychological variables such as stress, anxiety, and depression. The severity of psoriasis had a significant negative relation to social relationships and environmental domains of WHOQOL. QoL was significantly poor in patients with psoriasis with existing comorbidities like anxiety or depression. Conclusion: Patients suffering from psoriasis have a significant rate of depression, anxiety, and stress. This study signifies the relationship between psoriasis, Quality of life, and psychiatric comorbidities and the need to consider dermatological and psychological factors.

• 1.   World Health Organization. Mental health: new understanding, new hope. Geneva: World Health Organization; 2001.
• 2.   Naylor C, Parsonage M, McDaid D, Knapp M, Fossey M. Long-term conditions and mental health: the cost of comorbidities. London: The King’s Fund and Centre for Mental Health; 2012.
• 3.   Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Qualityof life in patients with psoriasis. Health Qual Life Outcomes 2006;4:35.
• 4.   Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P. Psychiatric morbidity in dermatological outpatients: anissue to be recognized. Br J Dermatol 2000;143:983-91.
• 5.   Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo and psoriasis: a comparative study from India. J Dermatol 2001;28:424-32.
• 6.   Sarkar S, Sarkar A, Saha R, Sarkar T. Psoriasis and psychiatric morbidity: a profile from a tertiary care centre of eastern India. J Fam Med Prim Care 2014;3:29-32.
• 7.   Kumar S, Kachhawha D, Das Koolwal G, Gehlot S, AwasthiA. Psychiatric morbidity in psoriasis patients: a pilot study.Indian J Dermatol Venereol Leprol 2011;77:625.
• 8.   Golpour M, Hosseini SH, Khademloo M, Ghasemi M, EbadiA, Koohkan F, et al. Depression and Anxiety Disorders amongPatients with Psoriasis: A Hospital-Based Case-ControlStudy. Dermatol Res Pract 2012;2012:381905.
• 9.   Fredriksson T, Pettersson U. Severe psoriasis - oral therapywith a new retinoid. Dermatologica 1978;157:238-44.
• 10.   Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validityof a brief depression severity measure. J Gen Intern Med 2001;16:606-13.
• 11.   Spitzer RL, Kroenke K, Williams JBW, Lowe B. A briefmeasure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-7.
• 12.   Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983;24:385-96.
• 13.   Development of the World Health Organization WHOQOLBREFquality of life assessment. The WHOQOL Group. Psychol Med 1998;28:551-8.
• 14.   Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A.Assessment of depression in subjects with psoriasis vulgarisand lichen planus. J Eur Acad Dermatol Venereol 2002;16:347-52.
• 15.   Devrimci-Ozguven H, Kundakci TN, Kumbasar H, BoyvatA. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000;14:267-71.
• 16.   Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. Theprevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 2014;134:1542–51.
• 17.   Nasreen S, Ahmed I, Effendi S. Frequency and magnitude ofanxiety and depression in patients with psoriasis vulgaris.J Coll Physicians Surg Pak 2008;18:397-400.
• 18.   Rabin F, Bhuiyan SI, Islam T, Haque MA, Islam MA.Psychiatric and psychological comorbidities in patients with psoriasis- a review. Mymensingh Med J 2012;21:780-6.
• 19.   Ader R, Cohen N, Felten D. Psychoneuroimmuno logy:interactions between the nervous system and the immune system. Lancet 1995;345:99-103.
• 20.   Sadock BJ, Sadock VA, Ruiz P. Anxiety Disorders:Introduction and Overview. In: Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. Philadelphia: Wolter Kluwer/Lippincott Williams & Wilkins; 2009. p.18402.
• 21.   Gascón MRP, Ribeiro CM, Bueno LM de A, Benute GRG,Lucia MCS de, Rivitti EA, et al. Prevalence of depression and anxiety disorders in hospitalized patients at the dermatology clinical ward of a university hospital. An Bras Dermatol 2012;87:403-7.
• 22.   Gupta MA, Gupta AK. Psychiatric and psychological comorbidityin patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003;4:833-42.
• 23.   Langley RGB, Krueger GG, Griffiths CEM. Psoriasis:epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64 Suppl 2:ii1823; discussion ii24-5.
• 24.   Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidalideation in psoriasis. Int J Dermatol 1993;32:188-90.
• 25.   Gupta MA, Gupta AK, Kirkby S, Schork NJ, Gorr SK, Ellis CN, et al. A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients. Gen Hosp Psychiatry 1989;11:166-73.
• 26.   Bedi TR. Psoriasis in North India. Geographical variations. Dermatologica 1977;155:310-4.
• 27.   Bedi TR. Clinical profile of psoriasis in North India. Indian J Dermatol Venereol Leprol 1995;61:202-5.
• 28.   Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. J Dermatol 1997;24:230-4.
• 29.   Okhandiar RP, Banerjee BN. Psoriasis in the tropics: Anepidemiological survey. J Indian Med Assoc 1963;41:550-6.
• 30.   Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006;154:325-31.
• 31.   Fortune DG, Richards HL, Griffiths CEM, Main CJ. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol 2002;41(Pt 2):157-74.
• 32.   Fried RG, Friedman S, Paradis C, Hatch M, Lynfield Y,Duncanson C, et al. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995;34:101-5.
• 33.   De Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review.J Investig Dermatol Symp Proc 2004;9:140-7.
• 34.   Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. DermatolBasel Switz 2006;212:123-7.
• 35.   Richards HL, Ray DW, Kirby B, Mason D, Plant D, Main CJ,et al. Response of the hypothalamicpituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol 2005;153:1114-20.

Data Sharing Statement

Funding